文献速递糖尿病性腺与生殖内分泌

激素使用与跨性别人群糖尿病发病率之间有关联吗?来自STRONG队列的数据

Is There a Link Between Hormone Use and Diabetes Incidence in Transgender People? Data From the STRONG Cohort.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

基于3个整合医疗系统电子健康记录的队列研究,纳入2869名跨女性成员及匹配的28300名顺性别女性和28258名顺性别男性,2133名跨男性成员及匹配的20997名顺性别女性和20964名顺性别男性,随访至2016年。跨女性队列的2型糖尿病患病率和发病率均高于顺性别女性参照组,OR为1.3(95%CI 1.1-1.5),HR为1.4(95%CI 1.1-1.8);其余比较组间无显著差异。作者认为跨女性人群2型糖尿病风险可能高于顺性别女性,但跨女性与顺性别男性之间的差异无法辨别,且跨女性或跨男性人群的2型糖尿病发生似乎与性别肯定激素治疗使用无关。

要点

  • 跨女性人群2型糖尿病患病率高于顺性别女性,OR为1.3(95%CI 1.1-1.5)。
  • 跨女性人群2型糖尿病发病率高于顺性别女性,HR为1.4(95%CI 1.1-1.8)。
  • 其余比较组间2型糖尿病患病率和发病率均无显著差异。

核心结论

  • 跨女性人群2型糖尿病风险可能高于顺性别女性,但与顺性别男性之间的相应差异无法辨别。
  • 跨女性或跨男性人群中2型糖尿病的发生似乎与性别肯定激素治疗使用无关的证据很少。

研究设计与样本

  • 基于电子健康记录的队列研究,纳入3个整合医疗系统的18岁及以上人员。
  • 队列包括2869名跨女性成员,按年龄、种族/民族、日历年和研究地点匹配28300名顺性别女性和28258名顺性别男性。
  • 队列包括2133名跨男性成员,同样匹配20997名顺性别女性和20964名顺性别男性。
  • 队列确定时间跨度为2006年至2014年的9年,随访延长至2016年。
  • 使用Cox比例风险模型和logistic回归模型分别分析2型糖尿病的发病率和患病率,所有分析均控制体重指数。

主要发现

  • 跨女性队列的2型糖尿病患病率高于顺性别女性参照组,OR为1.3(95%CI 1.1-1.5)。
  • 跨女性队列的2型糖尿病发病率高于顺性别女性参照组,HR为1.4(95%CI 1.1-1.8)。
  • 其余比较组间2型糖尿病患病率和发病率均无显著差异,在总体和在有性别肯定激素治疗证据的跨性别与性别多样人群中也均无显著差异。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Risk of type 2 diabetes mellitus (T2DM) in transgender and gender diverse (TGD) persons, especially those receiving gender-affirming hormone therapy (GAHT) is an area of clinical and research importance. METHODS: We used data from an electronic health record-based cohort study of persons 18 years and older enrolled in 3 integrated health care systems. The cohort included 2869 transfeminine members matched to 28 300 cisgender women and 28 258 cisgender men on age, race/ethnicity, calendar year, and site, and 2133 transmasculine members similarly matched to 20 997 cisgender women and 20 964 cisgender men. Cohort ascertainment spanned 9 years from 2006 through 2014 and follow-up extended through 2016. Data on T2DM incidence and prevalence were analyzed using Cox proportional hazards and logistic regression models, respectively. All analyses controlled for body mass index. RESULTS: Both prevalent and incident T2DM was more common in the transfeminine cohort relative to cisgender female referents with odds ratio and hazard ratio (95% CI) estimates of 1.3 (1.1-1.5) and 1.4 (1.1-1.8), respectively. No significant differences in prevalence or incidence of T2DM were observed across the remaining comparison groups, both overall and in TGD persons with evidence of GAHT receipt. CONCLUSION: Although transfeminine people may be at higher risk for T2DM compared with cisgender females, the corresponding difference relative to cisgender males is not discernable. Moreover, there is little evidence that T2DM occurrence in either transfeminine or transmasculine persons is attributable to GAHT use.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Islam N, Nash R, Zhang Q, et al. Is There a Link Between Hormone Use and Diabetes Incidence in Transgender People? Data From the STRONG Cohort. J Clin Endocrinol Metab. 2022. PMID: 34850912. doi:10.1210/clinem/dgab832

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。